Samsung Biologics, a leading contract development, and the manufacturing company announced its strategic collaboration with the Chinese biotech company, GeneQuantum. The partnership aims to develop an antibody-drug conjugate (ADC) to treat triple-negative breast cancer (TNBC), non-small-cell lung carcinoma (NSCLC), and other solid tumors. This collaboration signifies the accelerated entry of Samsung Biologics into the China market.
In 2019, the Chinese biopharmaceutical market accounted for 38.5 billion USD and is anticipated to grow at a 14.4% rate annually. Before a partnership with the Chinese company, Samsung Biologics has signed an agreement with APRINOIA Therapeutics, an innovative biotech firm, further marking the company’s accelerated entry and presence in the market.
GeneQuantum had earlier signed a Collateralized Debt Obligation (CDO) agreement with a Contract Development and Manufacturing Organization (CDMO) partner for its first asset but chose Samsung Biologics for its second antibody candidate. Owing to the recognized capabilities of the South Korean biotechnology company to achieve client satisfaction at its best, the company is in widespread discussion with various potential Chinese clients in the market.
Lately, GeneQuantum Healthcare received a Good to Proceed Letter from the US FDA's Investigational New Drug (IND) for its first anti-HER2 ADC asset, which was manufactured through its registered intelligent ligase-dependent conjugation technology platform
Samsung Biologics’ CDO business unit is reported to acquire nearly 60 contracts in two years, gaining acknowledgment in the global market due to the achievements it recorded in recent years. By taking 6 months for DS manufacturing and 7 months for DP manufacturing, the company has reduced the time needed for the development stage dramatically. It also revealed S-CHOice, its exclusive cell line technology, representing enhanced titers up to two-fold from the market average and upholds over 90% of cell viability. With a various partnership like these, particularly with the leading Chinese biotech organizations, the company focuses on further demonstrating its extensive CDO capabilities and technology in the market of China to deliver better access to innovative treatments for patients.